Cymat Days Sales Outstanding vs Capex To Depreciation Analysis

CYM Stock

CAD 0.10 0.02 16.67%

Cymat Technologies financial indicator trend analysis is way more than just evaluating Cymat Technologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cymat Technologies is a good investment. Please check the relationship between Cymat Technologies Days Sales Outstanding and its Capex To Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cymat Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Days Sales Outstanding vs Capex To Depreciation

Days Sales Outstanding vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cymat Technologies Days Sales Outstanding account and Capex To Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Cymat Technologies' Days Sales Outstanding and Capex To Depreciation is -0.07. Overlapping area represents the amount of variation of Days Sales Outstanding that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Cymat Technologies, assuming nothing else is changed. The correlation between historical values of Cymat Technologies' Days Sales Outstanding and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Sales Outstanding of Cymat Technologies are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Days Sales Outstanding i.e., Cymat Technologies' Days Sales Outstanding and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

-0.07

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Days Sales Outstanding

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from Cymat Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cymat Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cymat Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Enterprise Value is likely to climb to about 22.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 2.6 M in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	3.1M	3.1M	1.6M	1.9M
Depreciation And Amortization	177.8K	506.6K	456.0K	668.9K

Total Revenue Depreciation And Amortization

Cymat Technologies fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Stockholder Equity	Intangible Assets	Short Term Investments
Total Assets		0.18	0.26	0.53	0.44	0.7	0.41	-0.59	-0.35	0.69	0.62	0.74	-0.12	0.65	0.13	0.77	0.31	0.73	0.71	0.63	0.83	-0.22	0.31	0.55	0.01	-0.03
Short Long Term Debt Total	0.18		0.13	0.67	-0.7	0.42	0.1	0.54	-0.44	0.2	-0.2	0.42	-0.34	-0.17	-0.46	0.29	0.54	0.37	0.28	0.82	-0.09	0.44	0.37	0.43	0.23	-0.28
Other Current Liab	0.26	0.13		0.19	0.07	0.3	-0.07	-0.04	0.53	0.34	0.12	0.29	0.69	0.12	-0.03	-0.01	0.22	0.05	0.31	0.25	0.13	-0.02	-0.53	-0.27	-0.71	0.7
Total Current Liabilities	0.53	0.67	0.19		-0.39	0.63	0.3	0.09	-0.36	0.54	-0.01	0.69	-0.15	0.04	-0.38	0.62	0.07	0.65	0.52	0.87	0.19	0.45	0.31	0.46	-0.03	-0.05
Total Stockholder Equity	0.44	-0.7	0.07	-0.39		-0.04	0.14	-0.86	0.12	0.23	0.74	-0.1	0.14	0.73	0.6	0.1	-0.13	0.01	0.14	-0.4	0.71	-0.4	-0.07	-0.01	-0.05	0.09
Property Plant And Equipment Net	0.7	0.42	0.3	0.63	-0.04		0.29	-0.02	-0.33	0.76	0.02	0.92	-0.04	0.06	-0.31	0.79	0.44	0.72	0.73	0.76	0.25	-0.18	0.3	0.61	-0.1	0.04
Current Deferred Revenue	0.41	0.1	-0.07	0.3	0.14	0.29		-0.25	-0.39	0.53	0.3	0.21	-0.22	0.31	0.13	0.55	0.29	0.44	0.48	0.37	0.42	-0.1	0.41	0.53	0.19	-0.23
Net Debt	-0.59	0.54	-0.04	0.09	-0.86	-0.02	-0.25		0.01	-0.38	-0.88	-0.01	-0.04	-0.88	-0.35	-0.26	0.11	-0.1	-0.08	0.14	-0.84	0.35	-0.05	-0.06	0.02	-0.03
Retained Earnings	-0.35	-0.44	0.53	-0.36	0.12	-0.33	-0.39	0.01		-0.3	-0.15	-0.25	0.94	-0.17	0.06	-0.68	-0.38	-0.49	-0.3	-0.49	-0.29	-0.09	-0.98	-0.91	-0.88	0.91
Accounts Payable	0.69	0.2	0.34	0.54	0.23	0.76	0.53	-0.38	-0.3		0.38	0.57	-0.02	0.42	-0.12	0.74	0.44	0.63	0.64	0.62	0.53	-0.18	0.37	0.55	-0.08	-0.02
Cash	0.62	-0.2	0.12	-0.01	0.74	0.02	0.3	-0.88	-0.15	0.38		-0.03	-0.11	1.0	0.27	0.24	0.16	0.05	0.08	0.05	0.91	-0.1	0.17	0.19	0.16	-0.14
Non Current Assets Total	0.74	0.42	0.29	0.69	-0.1	0.92	0.21	-0.01	-0.25	0.57	-0.03		0.01	0.01	-0.28	0.75	0.27	0.75	0.72	0.77	0.24	-0.16	0.16	0.48	-0.19	0.15
Non Currrent Assets Other	-0.12	-0.34	0.69	-0.15	0.14	-0.04	-0.22	-0.04	0.94	-0.02	-0.11	0.01		-0.12	0.0	-0.42	-0.27	-0.27	-0.04	-0.26	-0.18	-0.14	-0.93	-0.75	-0.98	0.98
Cash And Short Term Investments	0.65	-0.17	0.12	0.04	0.73	0.06	0.31	-0.88	-0.17	0.42	1.0	0.01	-0.12		0.25	0.28	0.17	0.09	0.11	0.1	0.93	-0.11	0.19	0.22	0.15	-0.14
Net Receivables	0.13	-0.46	-0.03	-0.38	0.6	-0.31	0.13	-0.35	0.06	-0.12	0.27	-0.28	0.0	0.25		-0.09	-0.1	0.17	0.28	-0.37	0.41	-0.23	0.0	-0.05	0.08	-0.05
Common Stock Shares Outstanding	0.77	0.29	-0.01	0.62	0.1	0.79	0.55	-0.26	-0.68	0.74	0.24	0.75	-0.42	0.28	-0.09		0.34	0.79	0.7	0.7	0.49	-0.17	0.66	0.86	0.28	-0.34
Non Current Liabilities Total	0.31	0.54	0.22	0.07	-0.13	0.44	0.29	0.11	-0.38	0.44	0.16	0.27	-0.27	0.17	-0.1	0.34		0.32	0.36	0.54	0.23	-0.34	0.39	0.48	0.24	-0.28
Inventory	0.73	0.37	0.05	0.65	0.01	0.72	0.44	-0.1	-0.49	0.63	0.05	0.75	-0.27	0.09	0.17	0.79	0.32		0.9	0.73	0.43	-0.16	0.48	0.64	0.1	-0.18
Other Current Assets	0.71	0.28	0.31	0.52	0.14	0.73	0.48	-0.08	-0.3	0.64	0.08	0.72	-0.04	0.11	0.28	0.7	0.36	0.9		0.62	0.44	-0.16	0.29	0.57	-0.06	0.02
Total Liab	0.63	0.82	0.25	0.87	-0.4	0.76	0.37	0.14	-0.49	0.62	0.05	0.77	-0.26	0.1	-0.37	0.7	0.54	0.73	0.62		0.27	0.16	0.43	0.61	0.08	-0.16
Total Current Assets	0.83	-0.09	0.13	0.19	0.71	0.25	0.42	-0.84	-0.29	0.53	0.91	0.24	-0.18	0.93	0.41	0.49	0.23	0.43	0.44	0.27		-0.18	0.3	0.39	0.17	-0.17
Short Term Debt	-0.22	0.44	-0.02	0.45	-0.4	-0.18	-0.1	0.35	-0.09	-0.18	-0.1	-0.16	-0.14	-0.11	-0.23	-0.17	-0.34	-0.16	-0.16	0.16	-0.18		0.06	0.0	0.15	-0.14
Common Stock	0.31	0.37	-0.53	0.31	-0.07	0.3	0.41	-0.05	-0.98	0.37	0.17	0.16	-0.93	0.19	0.0	0.66	0.39	0.48	0.29	0.43	0.3	0.06		0.9	0.88	-0.92
Other Stockholder Equity	0.55	0.43	-0.27	0.46	-0.01	0.61	0.53	-0.06	-0.91	0.55	0.19	0.48	-0.75	0.22	-0.05	0.86	0.48	0.64	0.57	0.61	0.39	0.0	0.9		0.67	-0.71
Intangible Assets	0.01	0.23	-0.71	-0.03	-0.05	-0.1	0.19	0.02	-0.88	-0.08	0.16	-0.19	-0.98	0.15	0.08	0.28	0.24	0.1	-0.06	0.08	0.17	0.15	0.88	0.67		-0.99
Short Term Investments	-0.03	-0.28	0.7	-0.05	0.09	0.04	-0.23	-0.03	0.91	-0.02	-0.14	0.15	0.98	-0.14	-0.05	-0.34	-0.28	-0.18	0.02	-0.16	-0.17	-0.14	-0.92	-0.71	-0.99

Click cells to compare fundamentals

Cymat Technologies Account Relationship Matchups

Cymat Technologies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.9M	6.6M	6.2M	4.2M	4.0M	6.7M
Short Long Term Debt Total	1.1M	1.1M	1.0M	2.3M	2.6M	2.7M
Other Current Liab	177.7K	179.0K	222.7K	191.0K	171.9K	159.5K
Total Current Liabilities	1.4M	2.0M	2.2M	2.2M	4.5M	4.8M
Total Stockholder Equity	(889.5K)	2.9M	2.3M	(612.1K)	(2.8M)	(2.7M)
Property Plant And Equipment Net	1.2M	1.1M	1.1M	2.9M	2.4M	2.5M
Current Deferred Revenue	62.7K	182.3K	390.8K	240.2K	276.2K	140.7K
Net Debt	810.4K	(3.9M)	(1.5M)	2.0M	986.4K	1.0M
Retained Earnings	(81.7M)	(82.2M)	(87.0M)	(93.0M)	(97.3M)	(92.4M)
Accounts Payable	1.0M	1.5M	1.4M	1.5M	2.1M	1.1M
Cash	251.6K	5.0M	2.5M	324.0K	56.3K	53.5K
Non Current Assets Total	1.2M	1.1M	1.4M	2.9M	2.4M	4.7M
Cash And Short Term Investments	251.6K	5.0M	2.5M	324.0K	291.6K	277.1K
Net Receivables	203.9K	164.6K	837.8K	59.4K	38.0K	36.1K
Common Stock Shares Outstanding	40.4M	43.2M	53.7M	58.4M	65.7M	69.0M
Liabilities And Stockholders Equity	1.9M	6.6M	6.2M	4.2M	3.7M	6.9M
Non Current Liabilities Total	1.4M	1.7M	1.7M	2.6M	2.2M	1.2M
Inventory	130.1K	262.8K	1.2M	701.5K	1.2M	1.3M
Other Current Assets	26.5K	24.6K	266.7K	188.9K	170.0K	184.6K
Total Liab	2.8M	3.7M	3.8M	4.8M	6.8M	7.1M
Total Current Assets	612.1K	5.5M	4.8M	1.3M	1.6M	2.0M
Short Term Debt	83.8K	98.6K	121.7K	296.7K	341.2K	309.5K
Common Stock	72.9M	73.5M	79.9M	81.6M	93.8M	71.5M
Other Stockholder Equity	7.8M	7.9M	9.3M	10.6M	9.6M	9.1M
Other Liab	414.0K	748.5K	783.8K	581.3K	668.5K	525.3K
Net Tangible Assets	(889.5K)	2.9M	2.3M	(612.1K)	(703.9K)	(739.1K)
Property Plant Equipment	1.2M	1.1M	1.1M	2.9M	3.3M	3.4M
Net Invested Capital	(889.5K)	3.0M	2.5M	(469.2K)	(1.8M)	(1.7M)
Net Working Capital	(747.2K)	3.5M	2.6M	(934.6K)	(3.0M)	(2.8M)
Capital Stock	72.9M	73.5M	79.9M	81.6M	83.2M	84.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Cymat Stock Analysis

When running Cymat Technologies' price analysis, check to measure Cymat Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cymat Technologies is operating at the current time. Most of Cymat Technologies' value examination focuses on studying past and present price action to predict the probability of Cymat Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cymat Technologies' price. Additionally, you may evaluate how the addition of Cymat Technologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC